Futibatinib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameFutibatinib
Drug Alias NameLYTGOBITAS-120
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonistsFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[4] 
TargetsFibroblast growth factor receptor 4Fibroblast growth factor receptor 1Fibroblast growth factor receptor 3 +[4] 
Therapy Area/IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[20] 
Global Approved IndicationsBiliary Tract NeoplasmsCholangiocarcinoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/09/30
Country/TerritoryBelgiumCanadaUnited States +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTaiho Pharmaceutical Co LtdOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Taiho Pharma Netherlands BVTaiho Pharmaceutical Co Ltd +[6] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsCentral Nervous System Neoplasms +[11] 
Inactive IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[9] 

Other Information

ATC CodeN/A
Related LinksN/A